A marginal residual hazard to opposite direction was seen also for PgR status, tumor size, and the number of affected lymph nodes, suggesting an overall poor fit of the PREDICT ER-positive score for the BRCA2 carriers from CIMBA. This evidence concerns the gene BRCA2 and neoplasm.